Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics

 Breaking News
  • No posts were found

Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics

Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics

DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Merkel Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Merkel Cell Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

  • June 2024:- Ocellaris Pharma, Inc.- A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers. This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
  • DelveInsight’s Advanced Merkel Cell Carcinoma Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
  • The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.
  • Promising Advanced Merkel Cell Carcinoma Therapies such as Avelumab, BT-001, GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, OC-001, and others.

Stay informed about the cutting-edge advancements in Advanced Merkel Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

Advanced Merkel cell carcinoma Emerging Drugs Profile

  • Tidutamab: Xencor, Inc.

Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.

  • Cabozantinib: Exelixis

In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Merkel cell carcinoma.

Learn more about Advanced Merkel Cell Carcinoma Drugs Opportunities in our groundbreaking Advanced Merkel Cell Carcinoma Research and development projects @ Advanced Merkel Cell Carcinoma Unmet Needs

Advanced Merkel cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Advanced Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Advanced Merkel Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Merkel Cell Carcinoma Companies- Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.
  • Advanced Merkel Cell Carcinoma Therapies- Avelumab, BT-001, GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, OC-001, and others.
  • Advanced Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Merkel Cell Carcinoma Pipeline on our website @ Advanced Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Merkel cell carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Cabozantinib: Exelixis
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. IFx-Hu2.0: Morphogenesis
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Advanced Merkel cell carcinoma Key Companies
  15. Advanced Merkel cell carcinoma Key Products
  16. Advanced Merkel cell carcinoma- Unmet Needs
  17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
  18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
  19. Advanced Merkel cell carcinoma Analyst Views
  20. Advanced Merkel cell carcinoma Key Companies
  21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Categories